TimsTOF-Based DIA Proteomic Profiling of Cisplatin-Resistant and Sensitive MDA-MB-231 Triple-Negative Breast Cancer Cell Lines
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Prof. Sanjeeva Srivastava
PROVIDER: PXD063175 | JPOST Repository | Wed Apr 22 00:00:00 BST 2026
REPOSITORIES: jPOST
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| cisR1.d.zip | Other | |||
| cisR2.d.zip | Other | |||
| cisR3.d.zip | Other | |||
| cisS1.d.zip | Other | |||
| cisS2.d.zip | Other |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:This dataset includes mass spectrometry-based proteomic profiles of cisplatin-resistant (cisR) and cisplatin-sensitive (cisS) MDA-MB-231 triple-negative breast cancer (TNBC) cell lines. The study aimed to investigate the molecular alterations contributing to cisplatin resistance using data-independent acquisition (DIA) proteomics. Key findings revealed upregulation of extracellular matrix (ECM) remodeling proteins (e.g., COL6A1, COL6A3), drug efflux transporters (e.g., ABCC4), and membrane-associated resistance proteins (e.g., TIMP1, MMP-14, APP), highlighting their potential roles in chemoresistance. The data provide insights into resistance-associated signaling, metabolic pathways, and potential therapeutic targets in TNBC.
2026-04-07 | PXD062652 | JPOST Repository
Project description:Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that promotes higher risk of metastasis and cancer reoccurrence, subsequently reduces survival rate of cancer patients. Cisplatin is one of the potential anticancer drugs for treating TNBC. However, occurrence of cisplatin resistance still remains as one of the challenges to fully eradicate TNBC. Since presence of cancer stem cells (CSCs) often known as one of the contributors of drug resistance, investigation has been conducted, suggesting sorted CSC-like subpopulation to be more resistant to cisplatin as compared to parental cells, alongside with higher self-renewability. On the other hand, plethora evidences showed the transmission of exosomal-miRNAs are capable of promoting drug resistance in breast cancers. In this study, we aim to elucidate the differential expression of exosomal-microRNAs profile and reveal the potential target genes in correlation to cisplatin resistance associated with CSC-like subpopulation by using TNBC cell line (MDA-MB-231). Utilizing next generation sequencing and Nanostring techniques, cisplatin-induced dysregulation of exosomal-miRNAs were evaluated in maximal for CSC-like subpopulation as compared to parental cells. Intriguingly, cisplatin induced a relatively oncogenic exosomal-miRNAs profile derived from treated CSC-like subpopulation as compared to treated parental cells, which may correlate to enhancement of drug resistance and maintenance of CSCs. Among the detected exosomal-miRNA profile in treated CSC-like subpopulation, unique clusters of miRNAs namely miR-221-3p, miR-196a-5p, miR-17-5p and miR-126-3p were predicted to target on six genes (ATXN1, LATS1, GSK3β, ITGA6, JAG1 and MYC), aligned with previous finding which demonstrated dysregulation of these genes in treated CSC-like subpopulation. Our results highlight the potential correlation of exosomal-miRNAs and their target genes as well as novel perspectives of the corresponding pathways that may be essential to contribute to the attenuated cytotoxicity of cisplatin in CSC-like subpopulation.
2022-06-20 | GSE178310 | GEO
Project description:Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that promotes higher risk of metastasis and cancer reoccurrence, subsequently reduces survival rate of cancer patients. Cisplatin is one of the potential anticancer drugs for treating TNBC. However, occurrence of cisplatin resistance still remains as one of the challenges to fully eradicate TNBC. Since presence of cancer stem cells (CSCs) often known as one of the contributors of drug resistance, investigation has been conducted, suggesting sorted CSC-like subpopulation to be more resistant to cisplatin as compared to parental cells, alongside with higher self-renewability. On the other hand, plethora evidences showed the transmission of exosomal-miRNAs are capable of promoting drug resistance in breast cancers. In this study, we aim to elucidate the differential expression of exosomal-microRNAs profile and reveal the potential target genes in correlation to cisplatin resistance associated with CSC-like subpopulation by using TNBC cell line (MDA-MB-231). Utilizing next generation sequencing and Nanostring techniques, cisplatin-induced dysregulation of exosomal-miRNAs were evaluated in maximal for CSC-like subpopulation as compared to parental cells. Intriguingly, cisplatin induced a relatively oncogenic exosomal-miRNAs profile derived from treated CSC-like subpopulation as compared to treated parental cells, which may correlate to enhancement of drug resistance and maintenance of CSCs. Among the detected exosomal-miRNA profile in treated CSC-like subpopulation, unique clusters of miRNAs namely miR-221-3p, miR-196a-5p, miR-17-5p and miR-126-3p were predicted to target on six genes (ATXN1, LATS1, GSK3β, ITGA6, JAG1 and MYC), aligned with previous finding which demonstrated dysregulation of these genes in treated CSC-like subpopulation. Our results highlight the potential correlation of exosomal-miRNAs and their target genes as well as novel perspectives of the corresponding pathways that may be essential to contribute to the attenuated cytotoxicity of cisplatin in CSC-like subpopulation.
2022-06-20 | GSE178307 | GEO
Project description:Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that promotes higher risk of metastasis and cancer reoccurrence, subsequently reduces survival rate of cancer patients. Cisplatin is one of the potential anticancer drugs for treating TNBC. However, occurrence of cisplatin resistance still remains as one of the challenges to fully eradicate TNBC. Since presence of cancer stem cells (CSCs) often known as one of the contributors of drug resistance, investigation has been conducted, suggesting sorted CSC-like subpopulation to be more resistant to cisplatin as compared to parental cells, alongside with higher self-renewability. On the other hand, plethora evidences showed the transmission of exosomal-miRNAs are capable of promoting drug resistance in breast cancers. In this study, we aim to elucidate the differential expression of exosomal-microRNAs profile and reveal the potential target genes in correlation to cisplatin resistance associated with CSC-like subpopulation by using TNBC cell line (MDA-MB-231). Utilizing next generation sequencing and Nanostring techniques, cisplatin-induced dysregulation of exosomal-miRNAs were evaluated in maximal for CSC-like subpopulation as compared to parental cells. Intriguingly, cisplatin induced a relatively oncogenic exosomal-miRNAs profile derived from treated CSC-like subpopulation as compared to treated parental cells, which may correlate to enhancement of drug resistance and maintenance of CSCs. Among the detected exosomal-miRNA profile in treated CSC-like subpopulation, unique clusters of miRNAs namely miR-221-3p, miR-196a-5p, miR-17-5p and miR-126-3p were predicted to target on six genes (ATXN1, LATS1, GSK3β, ITGA6, JAG1 and MYC), aligned with previous finding which demonstrated dysregulation of these genes in treated CSC-like subpopulation. Our results highlight the potential correlation of exosomal-miRNAs and their target genes as well as novel perspectives of the corresponding pathways that may be essential to contribute to the attenuated cytotoxicity of cisplatin in CSC-like subpopulation.
2022-06-20 | GSE178305 | GEO
Project description:To define the ferroptosis landscape of basal-like and non-basal like TNBC and explore precision therapeutic opportunities, we integrated proteomics data to infer ferroptosis activity across TNBC subtypes.
2026-02-10 | PXD074094 | Pride
Project description:Despite advances in cancer therapy, drug resistance remains a major obstacle in a range of cancer types, often driven by overexpression of ATP-binding cassette (ABC) transporters that restrict intracellular drug accumulation. Our previous studies identified the BRG1-p300 transcriptional complex at the promoters of specific ABC transporter genes. We used basal and induced doxorubicin-resistant triple-negative breast cancer (TNBC) cell lines to analyze changes in ABC transporter expression and drug accumulation following PARP1 inhibition. Moreover, the effect of commonly used antioxidants on the repressive effect of Veliparib against ABC genes was verified. ChIP-Seq was performed to identify transcription factor mediating PARP1-dependent ABC gene regulation. PARP1 inhibition or silencing of PARP1/HPF1 complex components downregulated ABCC and ABCG2 transporters, leading to increased intracellular accumulation of chemotherapeutic drugs in doxorubicin-resistant cells. Notably, suppression of genotoxic stress via antioxidant treatment reverses the inhibitory effect of Veliparib on ABC transporter expression. We identified SMARCA1 as a key regulator of PARP1-dependent expression of ABCC genes. SMARCA1 is a key effector of PARP1/p300-mediated regulation of ABC transporters and represents a potential therapeutic target in doxorubicin-resistant TNBC. These findings support the development of combinatorial strategies involving PARP1 inhibitors and chromatin remodeling modulators in refractory breast cancers.
2025-12-04 | GSE312249 | GEO
Project description:Despite advances in cancer therapy, drug resistance remains a major obstacle in a range of cancer types, often driven by overexpression of ATP-binding cassette (ABC) transporters that restrict intracellular drug accumulation. Our previous studies identified the BRG1-p300 transcriptional complex at the promoters of specific ABC transporter genes. We used basal and induced doxorubicin-resistant triple-negative breast cancer (TNBC) cell lines to analyze changes in ABC transporter expression and drug accumulation following PARP1 inhibition. Moreover, the effect of commonly used antioxidants on the repressive effect of Veliparib against ABC genes was verified. ChIP-Seq was performed to identify transcription factor mediating PARP1-dependent ABC gene regulation. PARP1 inhibition or silencing of PARP1/HPF1 complex components downregulated ABCC and ABCG2 transporters, leading to increased intracellular accumulation of chemotherapeutic drugs in doxorubicin-resistant cells. Notably, suppression of genotoxic stress via antioxidant treatment reverses the inhibitory effect of Veliparib on ABC transporter expression. We identified SMARCA1 as a key regulator of PARP1-dependent expression of ABCC genes. SMARCA1 is a key effector of PARP1/p300-mediated regulation of ABC transporters and represents a potential therapeutic target in doxorubicin-resistant TNBC. These findings support the development of combinatorial strategies involving PARP1 inhibitors and chromatin remodeling modulators in refractory breast cancers.
2025-12-04 | GSE312254 | GEO
Project description:Triple-Negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is associated with poor prognosis due to its propensity to form metastases. Unfortunately, the current treatment options are limited to chemotherapy such that identification of actionable targets are needed. The receptor tyrosine kinase AXL plays a role in the tumor cell dissemination and its expression in TNBC correlates with poor patients? survival. Here, we explored whether exploiting an AXL knockdown gene signature in TNBC cells may offer an opportunity for drug repurposing. To this end, we queried the PharmacoGx pharmacogenomics platform with an AXL gene signature which revealed Phenothiazines, a class of Dopamine Receptors antagonists (Thioridazine, Fluphenazine and Trifluoperazine) typically used as anti-psychotics. We next tested if drugs may be active to limit growth and metastatic progression of TNBC cells, similarly to AXL depletion. We found that the Phenothiazines were able to reduce cel l invasion, proliferation and viability, and also increased apoptosis of TNBC cells in vitro. Mechanistically, these drugs did not affect AXL activity but instead reduced PI3K/AKT/mTOR and ERK signaling. When administered to mice bearing TNBC xenografts, these drugs showed were able to reduce tumor growth and metastatic burden. Collectively, these results suggest that these antipsychotics are novel anti-tumor and anti-metastatic agents that could potentially be repurposed, in combination with standard chemotherapy, for use in TNBC.
2019-04-01 | GSE120268 | GEO
Project description:This study investigates the transcriptomic alterations induced by a novel cyclometalated iridium(III) compound, CIr2, in triple-negative breast cancer (TNBC) cells. MDA-MB-231 cells were treated with CIr2 for 24 h, followed by RNA sequencing to profile global gene expression changes. The RNA-seq data were integrated with functional assays and morphological analyses to explore cellular responses associated with mitochondrial dysfunction, reactive oxygen species production, endoplasmic reticulum stress, and MAPK signaling. This dataset provides a resource for examining CIr2-induced transcriptional programs related to non-apoptotic cell death pathways in TNBC cells.
2026-01-21 | GSE316771 | GEO
Project description:Single-cell transcriptional lineage tracing TNBC MDA-MB-231
| PRJEB53139 | ENA